Highlights from BCANTT24
The annual BCAN Bladder Cancer Think Tank Meeting is the premier annual bladder cancer-specific medical meeting in North America. Since its inception in 2006, the Think Tank meeting has focused on identifying obstacles and creating solutions in bladder cancer research, and has fostered discussions to help define priorities for advancing bladder cancer research.
Invited participants include urologists, oncologists, researchers, pathologists, social scientists, patient advocates and industry representatives, all who are dedicated to improving the diagnosis and treatment of bladder cancer.
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, shared on X:
“Stellar talk by amazing Andrea Apolo on 1L data in metastatic UC! Huge progress with practice changing data.”
Mary Weinstein Dunn, Associate Professor of Medicine at Northwestern University:
“Proud of my UNC teammates Kathryn Hacker Gessner and Sean Clark-Garvey as they present their important research at BCANTT24. Their ongoing commitment to bladder cancer research will shape the future of patient care. It’s a team effort, w/ special shout outs to…”
Shilpa Gupta, Director of Genitourinary Medical Oncology at Taussig Cancer Institute:
“Sarah P. Psutka kicks off patient centered clinical research YIA! Amazing leadership by Sarah and Peter Clark for the Bladder Cancer Advocacy Network YIA!”
Laura Bukavina, Urologic Oncologist at Cleveland Clinic:
“Incredible amount of work and dedication went into our Cystectomy book by the whole team including Rebecca Campbell, Nima Almassi, Chris Weight.. it’s the absolute best resource and we are so excited to hopefully share it everyone soon!”
Karine Tawagi, Assistant Professor of Clinical Medicine and Associate Program Director at the University of Illinois:
“2015 vs 2024 National Comprehensive Cancer Network guidelines for Advanced Bladder Cancer Remarkable how far we have come in 10 years as we have improved our treatment options for better patient outcomes in Bladder Cancer.”
For more information visit oncodaily.com
